Objective: The aim of this study was to determine whether equol excretion status and plasma hormone and leptin concentrations can be influenced by consumption of a probiotic supplement. A secondary focus was to investigate whether male equol excretors have a hormone profile consistent with reduced prostate cancer risk.
INTRODUCTION

G
iven the wide disparity in soy food consumption between Asian populations at low risk for prostate cancer and Western populations at high risk for prostate cancer 1 and epidemiologic studies that support a protective effect of soy foods on prostate cancer risk, [2] [3] [4] there has been great interest in identifying the active component of soy foods. Attention has been focused on phytoestrogens, compounds abundant in traditional soy foods, which are thought to decrease prostate cancer risk in part by altering steroid hormone metabolism. 5, 6 Of particular interest is the phytoestrogen metabolite, equol. Equol is thought to be more estrogenic than its pre-cursor daidzein, 7 but not all humans produce the metabolite. Following a soy challenge, equol is excreted in the urine by 20% to 40% of the population. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Given that premenopausal equol excretors may have a hormone profile consistent with reduced breast cancer risk, 17 it is possible that equol excretion also may alter hormones and influence prostate cancer risk in men. In fact, epidemiologic studies have shown significantly fewer equol excretors among prostate cancer cases than controls. 18, 19 Because equol production is dependent on the bacterial metabolism of daidzein, it may be possible for nonexcretors to become excretors. Dietary factors are thought to alter the composition of human intestinal flora, 20 and Lu et al. reportedly increased equol excretion in premenopausal women following soy milk consumption. 21 In addition, specific strains of probiotic bacteria such as bifidobacteria were shown to increase the conversion of daidzein to equol in vitro. 22 Despite these data, equol excretion was not altered after soy protein or wheat bran consumption, 14 and in two recent reports, supplementation with probiotic bacteria did not alter equol excretion status. 9, 10 Probiotic supplementation may have the potential to independently alter circulating steroid hormone and leptin concentrations in a beneficial direction with respect to prostate cancer. Probiotic bacteria such as lactobacilli and bifidobacteria have low ␤-glucuronidase activity, 23 which could theoretically reduce enterohepatic circulation of steroid hormones by decreasing the hydrolysis of conjugated hormones in the intestine. A strain of lactobacilli was also shown to reduce plasma leptin concentrations, 24 which could potentially inhibit prostate cancer growth through the indirect activation of peroxisome proliferator-activated receptor ␥ (PPAR␥).
The authors hypothesized that equol excretion may be a marker for a bacterial environment conducive to the decreased enterohepatic circulation of androgens, which is associated with reduced prostate cancer risk. The primary purpose of this study was to determine whether equol excretion or hormone concentrations are influenced by the consumption of probiotic bacteria, and the secondary aim was to evaluate whether men who excrete equol have a hormone profile consistent with reduced prostate cancer risk.
MATERIALS AND METHODS
Thirty-nine (39) healthy men, 18 to 37 years old, were selected from the Minneapolis/St. Paul metropolitan area after an initial screening and a detailed self-administered questionnaire. Subjects were recruited by newspaper advertisements, posters, and class announcements at the University of Minnesota. Exclusionary criteria included BMI Ͻ18 or Ͼ30 kg/m 2 , antibiotic or exogenous hormone use within the last 3 months, probiotic supplement use within the last 30 days, alcohol consumption greater than 7 drinks/week, chronic health problems, regular medication use including aspirin, weight change of more than 4.5 kg (10 pounds) within the previous year or more than 2.3 kg (5 pounds) within the previous 2 months, and soy allergy. The 31 subjects who completed the entire study included 21 (68%) Caucasians, five (16%) Asians, two African Americans, one South American, one East Indian, and one Hispanic.
Experimental design and diet
The University of Minnesota Institutional Review Board: Human Subjects Committee approved the study protocol. Two-thirds of the subjects were randomized to receive probiotic and one-third randomized to receive placebo capsules for approximately 2 months (57 days) in a single-blinded, parallel-arm design. Subjects were free-living and supplemented their typical diets with a 4-day soy challenge on days 1 and 57. Subjects consumed probiotic or placebo capsules daily beginning on days 5 through day 61.
Subjects consumed their habitual diets, but they received detailed instructions about excluding soy products and fermented foods. Subjects also were instructed to consume three placebo or probiotic-containing capsules daily on an empty stomach. Each probiotic capsule contained a total of 10 9 colony-forming units (CFU) of Lactobacillus acidophilus and Bifidobacterium longum strain DDS ® ϩ1 and 10 to 15 mg fructooligosaccharide (UAS Laboratories, Minnetonka, MN). The placebo capsules (Gallipot ® Inc.; St. Paul, MN) contained rice starch and were of similar size, shape, and packaging as the probiotic capsules. For the 4-day soy challenge, subjects consumed soy protein isolate (The Solae Company, St. Louis, MO) providing 0.49 g protein and 0.84 mg isoflavones (aglycone units) per kg body weight per day (37 Ϯ 5 g protein and 63 Ϯ 9 mg isoflavones/day). The isoflavones in the soy protein isolate were 57% genistein, 35% daidzein, and 8% glycitein, analyzed by Dr. Pat Murphy, Department of Food Science and Human Nutrition, Iowa State University. Given known information about the pharmacokinetics of isoflavones, provision of this dose for 4 days is sufficient to separate equol excretors from nonexcretors.
Study procedures
On days 1 and 57, subject height was measured, body weight was obtained in a hospital gown, and fasting blood was drawn in heparinized tubes. Plasma was separated, ascorbic acid and sodium azide were added to a final concentration of 0.1%, and aliquots were frozen at Ϫ70°C until analysis.
Subjects began collecting 24-hour urine output the morning of days 4 and 60, the final day of each 4-day soy challenge. Urine was collected in plastic containers containing 1 g of ascorbic acid per liter and separated into aliquots after the addition of sodium azide to a final concentration of 0.1%. Aliquots were frozen at Ϫ20°C until analysis. Urinary creatinine was measured by dry slide chemistry with a VITROS ® Clinical Chemistry Analyzer (Ortho-Clinical Diagnostics; Raritan, NJ).
On days 1 and 57, dietary data were collected with the Health Habits and History Questionnaire, 25 a food frequency questionnaire containing 100 items that incorporates the nutrient content and portion size of foods into the final analysis.
Analytical methods
All plasma samples were analyzed for testosterone (T), dihydrotestosterone (DHT), androstanediol glucuronide (AAG), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and leptin. Steroid hormones were analyzed by radioimmunoassay, and leptin was analyzed by immunoradiometric assay (Diagnostics Systems Laboratories, Inc., Webster, TX). All analyses for each hormone were performed in one batch and all assays required 125 I-labeled analyte. Intra-assay variabilities were Ͻ4% for all analytes: 1.5% for T, 3.5% for DHT, 1.4% for AAG, 1.5% for A, 3.3% for DHEAS, 1.5% for SHBG, and 2.6% for leptin.
Urine was analyzed for genistein, glycitein, daidzein, O-desmethylangolensin (O-Dma), and equol by ion-exchange chromatography and isotope dilution gas chromatography mass spectrometry as described previously. 26 Intra-assay coefficients of variation were as follows: 8.5% for genistein, 12.6% for glycitein, 4.9% for daidzein, 6.5% for O-Dma, and inter-assay coefficients of variation were as follows: 6.4% for genistein, 40.8% for glycitein, 16.4% for daidzein, and 20.5% for O-Dma.
Dietary data were analyzed with DietSys Software version 4.0 (National Cancer Institute, 1997) by a single dietitian. Diets were evaluated for energy, protein, carbohydrate, fat, fiber, calcium, phosphorus, iron, sodium, potassium, zinc, magnesium, vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin C, folate, vitamin E, and vitamin B 6 content.
Statistical methods
There are no established levels of equol excretion to separate equol excretors from nonexcretors, but subjects fell into two distinct categories. Equol excretors excreted between 5000 and 38000 nmol per day, and equol excretion was undetectable in nonexcretors. The lower limit of sensitivity for this assay was 1800 nmol per day. This detection limit is consistent with that of Lampe et al. 14 Statistical analysis was performed using the Statistical Analysis System (SAS Institute, Inc., Cary, NC) version 8.2. Unpaired t-tests were used to compare baseline anthropometric measures, dietary factors, hormones, and phytoestrogens between probiotic and placebo groups and between equol excretors and non-excretors. Changes from baseline to postintervention between probiotic and placebo PROBIOTICS AND PHYTOESTROGEN METABOLISM 889 
RESULTS
Of the 39 subjects who began the study, 31 men completed all study requirements (21% dropout rate). One subject did not provide baseline dietary information; thus, data from 30 men were included in the dietary analysis.
Subject characteristics, energy and macronutrient intake, hormone concentrations, and phytoestrogen and metabolite excretion at baseline are shown in Table 1 (micronutrient data not shown). There were no significant differences in age, body weight, BMI, or dietary factors between the probiotic and placebo groups at baseline. Plasma T concentrations were lower in the probiotic group at baseline (p ϭ 0.02), and there was a trend toward lower baseline DHT concentrations in the probiotic group (p ϭ 0.08). Baseline phytoestrogen and metabolite excretion was not significantly different between the probiotic and placebo groups.
As expected, a significant positive correlation was found between BMI and leptin (r ϭ 0.43, p ϭ 0.01). Testosterone was positively correlated to SHBG (r ϭ 0.36, p ϭ 0.045) and inversely correlated to BMI (r ϭ Ϫ0.59, p ϭ 0.0005) and leptin (r ϭ Ϫ0.44, p ϭ 0.01). Significant correlations were also seen between T and DHT (r ϭ 0.51, p ϭ 0.004), DHT and SHBG (r ϭ 0.42, p ϭ 0.02), and DHEAS and A (r ϭ 0.55, p ϭ 0.001).
At baseline, DHEAS showed a significant inverse correlation with protein intake (r ϭ Ϫ0.45, p ϭ 0.01) and O-Dma excretion (r ϭ Ϫ0.39, p ϭ 0.03). Total energy intake was significantly associated with O-Dma (r ϭ 0.41, p ϭ 0.03), glycitein (r ϭ 0.42, p ϭ 0.02), and borderline associated with daidzein excretion (r ϭ 0.36, p ϭ 0.05). Protein intake was significantly correlated with O-Dma (r ϭ 0.55, p ϭ 0.002), glycitein (r ϭ 0.38, p ϭ 0.04), and daidzein excretion (r ϭ 0.38, p ϭ 0.04). Carbohydrate intake was significantly correlated to glycitein (r ϭ 0.42, p ϭ 0.03) and borderline associated with O-Dma (r ϭ 0.34, p ϭ 0.07) and daidzein excretion (r ϭ 0.36, p ϭ 0.05). Fiber intake was correlated to glycitein (r ϭ 0.43, p ϭ 0.02) and borderline associated with O-Dma (r ϭ 0.32, p ϭ 0.09) and daidzein excretion (r ϭ 0.33, p ϭ 0.08).
Changes in body weight, energy and macronutrient intake, hormone concentrations, and phytoestrogen and metabolite excretion are shown in Table 2 . There were no significant changes in body weight or dietary factors for either the probiotic or placebo group during the intervention and no significant differences between groups. No significant changes from baseline to study end were found for DHT, DHEAS, AAG, A, SHBG, or leptin for either group, and no significant differences were found between groups, although there was a trend toward a greater decrease in T in the placebo group (p ϭ 0.15). Changes in urinary genistein, glycitein, daidzein, and O-Dma were not significantly different between probiotic and placebo groups, but there was a significant within-group change from baseline in O-Dma excretion for the probiotic group (p ϭ 0.02).
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Nineteen percent (19%) of men in this study (6 out of 31) were equol excretors. Equol excretion did not change significantly for equol excretors following the 2-month intervention in either the probiotic or placebo group (Table 3) . Results were the same whether equol excretion was expressed as nmol per day or nmol per mg urinary creatinine. Though two men in the probiotic group (50%) excreted more equol postintervention when compared to baseline, two men in the placebo group (100%) also increased equol excretion during the study. Two subjects (one from each group) increased equol excretion by twofold. The mean change in equol excretion was not different between probiotic and placebo groups. Equol excretion status was not altered for any subject (e.g., nonexcretors did not become excretors).
Baseline subject characteristics, energy and macronutrient intake, hormone concentrations, and phytoestrogen and metabolite excretion of equol excretors and nonexcretors are presented in Table 4 . At baseline, there were no significant differences between equol excretors (n ϭ 6) and nonexcretors (n ϭ 25) with regard to age, body weight, BMI, total energy intake, protein, carbohydrate, fat, or fiber. Equol ex- 
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DISCUSSION
The authors' hypothesis that probiotic consumption would alter equol production was not proved true in this study, although the study may have been underpowered to detect true differences; thus the results of this study should be interpreted with caution. Probiotic consumption neither increased equol excretion in equol excretors nor converted nonexcretors into excretors. These results are consistent with other reports of studies in which equol excretion status was not altered by administration of a soy or wheat bran supplement, 14 or a probiotic supplement, 10 although one study showed that nonexcretors became excretors after consumption of soy milk. 21 Because subjects in this study consumed only one dose of soy milk before baseline classification of equol excretion, the study conclusions may be limited.
Urinary genistein, glycitein, and daidzein excretion was unaltered by probiotic consumption, but O-Dma excretion decreased significantly from baseline in the probiotic group, although the change was not significantly different from that of the placebo group. This result is consistent with another report in postmenopausal women that showed O-Dma excretion tended to decrease with probiotic consumption. 9 Perhaps the introduction of probiotic bacteria decreased clostridia populations, 27, 28 which have been shown to cleave the C-ring of daidzein to produce O-Dma. 29 The present study did not show that probiotic consumption influenced reproductive hormone concentrations. These results are in contrast to two studies in which ␤-glucuronidase activity was decreased in subjects following 4-week consumption of L. acidophilus 30 or 5-week consumption of B. longum 31 at doses comparable to this study. It is possible that variation in bacterial strains could account for these differing results or that decreased ␤-glucuronidase activity was not sufficient to significantly reduce plasma hormone concentrations.
Consumption of probiotic bacteria did not decrease plasma leptin concentrations in this study, although a previously reported randomized intervention showed that administration of a rose hip beverage containing about 10 10 CFU of L. plantarum 299v resulted in a 37% decrease in plasma leptin concentrations. 24 The authors hypothesized that lactobacilli produced propionic acid, which could decrease plasma leptin concentrations by ligand activation of PPAR␥. Differences in lactobacilli species could account for the discrepancy between this study results and those of Naruszewicz et al.
The authors also evaluated the relationships among base- 33 The authors also found a significant inverse relationship between DHEAS and O-Dma excretion.
To the authors' knowledge, these two variables have not been previously correlated. The authors did not find plasma hormone concentrations to differ between male equol excretors and nonexcretors; however, the low sample of equol excretors in this study limits this finding. Specifically, male equol excretors in this study did not exhibit lower levels of androgens or higher levels of SHBG, shown to be associated with reduced prostate cancer risk. [34] [35] [36] [37] A similar study of 36 premenopausal women 10 reported that premenopausal equol excretors did not have hormone profiles associated with reduced breast cancer risk.
The authors also compared equol excretors and nonexcretors with regard to phytoestrogen and metabolite excretion. Although two studies found that equol excretors produced less O-Dma and daidzein than nonexcretors, 15,38 the authors found no such relationship.
Although it was found that urinary excretion of a number of phytoestrogens and phytoestrogen metabolites was related to energy and macronutrient intake, this did not hold true for equol. These results differ from a previous report showing equol excretion status to be positively correlated with meat intake, the fat-to-fiber ratio, and total fat intake. 39 Equol excretors also have been shown to consume less fat and more carbohydrate as a fraction of energy intake. 13, 16 Contrary to these data, the authors' results, as well as those of others 9, 10, 14, 15, 17 report no dietary differences between equol excretors and nonexcretors, although these results are limited by the degree of sensitivity afforded by this dietary assessment tool and low power to detect true differences between equol excretors and nonexcretors.
CONCLUSIONS
Two-month consumption of a probiotic supplement containing L. acidophilus and B. longum did not alter equol excretion, plasma hormone, or leptin concentrations in male subjects. In addition, the authors were not able to show that male equol excretors had a hormone profile consistent with reduced prostate cancer risk, perhaps because of the low sample of equol excretors in this study. Consumption of total energy, protein, carbohydrate, and fiber were positively correlated to a number of phytoestrogens and phytoestrogen metabolites, including daidzein, glycitein, and O-Dma, but not equol. Future research should focus on the dose, duration, and strain of probiotic bacteria that may influence colonic bacterial activity and phytoestrogen metabolism.
